A new drug, called orforglipron, can help people with diabetes manage their A1C and weight, according to topline results from ...

For patients with diabetes, semaglutide use is associated with an increased risk for nonarteritic anterior ischemic optic neuropathy.

Oral semaglutide cuts major heart risks in people with type 2 diabetes by 14%, offering a powerful pill-based option. Both ...

Seeking Alpha analyst Stephen Ayers shares his views on which weight-loss drug stock looks most attractive for investors ...

Drugmaker Eli Lilly said that in Phase 3 studies of over 550 adults, their oral GLP-1 pill, orforglipron, could reduce ...

HealthDay News — The rate of emergency department visits for adverse events among patients dispensed semaglutide is low, with most visits involving gastrointestinal effects, according to a research ...

People are ‘microdosing’ weight-loss drugs like Ozempic. A GP explains the risks - Millions of people worldwide are now using ...

Researchers found that by December 2023, more than 1 in 3 of the medications being started for type 2 diabetes treatment were GLP-1RA-based medications.

Certain foods can worsen GI side effects from GLP-1 durgs. Learn which foods to avoid and which to choose instead.

Adding Farxiga (dapagliflozin) to standard care significantly reduced the risk of death or worsening heart failure in older ...

RAs, might offer new ways to reduce dementia risk. Discover the latest research and what it means for Alzheimer's treatment.

In the Phase III EXPECTS trial, patients experiencing mostly mild posterior circulation ischemic stroke who were ineligible ...